Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 12 | 2019 | 198 | 2.830 |
Why?
|
| Prostatectomy | 14 | 2016 | 476 | 2.560 |
Why?
|
| Postoperative Complications | 20 | 2017 | 2348 | 2.260 |
Why?
|
| Urethra | 7 | 2020 | 116 | 2.250 |
Why?
|
| Prostatic Hyperplasia | 11 | 2016 | 91 | 1.990 |
Why?
|
| Urinary Sphincter, Artificial | 8 | 2019 | 14 | 1.980 |
Why?
|
| Penis | 5 | 2015 | 61 | 1.720 |
Why?
|
| Reoperation | 7 | 2017 | 611 | 1.550 |
Why?
|
| Botulinum Toxins, Type A | 6 | 2017 | 51 | 1.420 |
Why?
|
| Urethral Diseases | 3 | 2015 | 15 | 1.270 |
Why?
|
| Urinary Bladder | 10 | 2020 | 249 | 1.270 |
Why?
|
| Risk Assessment | 6 | 2016 | 2345 | 1.250 |
Why?
|
| Patient Readmission | 4 | 2017 | 367 | 1.230 |
Why?
|
| Neuromuscular Agents | 5 | 2017 | 28 | 1.230 |
Why?
|
| Urologic Diseases | 6 | 2016 | 44 | 1.170 |
Why?
|
| Cystectomy | 8 | 2016 | 110 | 1.110 |
Why?
|
| Ureter | 4 | 2016 | 96 | 1.110 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2017 | 90 | 1.090 |
Why?
|
| Sex Reassignment Surgery | 3 | 2017 | 34 | 1.080 |
Why?
|
| Suburethral Slings | 5 | 2016 | 77 | 1.070 |
Why?
|
| Penile Prosthesis | 4 | 2017 | 25 | 1.050 |
Why?
|
| Penile Diseases | 2 | 2015 | 8 | 0.990 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 185 | 0.950 |
Why?
|
| Urinary Diversion | 5 | 2016 | 42 | 0.920 |
Why?
|
| Robotic Surgical Procedures | 3 | 2016 | 327 | 0.780 |
Why?
|
| Urinary Retention | 4 | 2014 | 42 | 0.770 |
Why?
|
| Laparoscopy | 8 | 2016 | 783 | 0.740 |
Why?
|
| Urologic Surgical Procedures | 9 | 2017 | 150 | 0.710 |
Why?
|
| Urinary Incontinence | 6 | 2014 | 216 | 0.690 |
Why?
|
| Urethral Stricture | 2 | 2015 | 14 | 0.680 |
Why?
|
| Abdominal Cavity | 1 | 2020 | 18 | 0.680 |
Why?
|
| Replantation | 2 | 2016 | 36 | 0.650 |
Why?
|
| Male | 53 | 2020 | 43249 | 0.620 |
Why?
|
| Humans | 77 | 2020 | 91074 | 0.590 |
Why?
|
| Incontinence Pads | 2 | 2016 | 4 | 0.580 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 259 | 0.560 |
Why?
|
| Suture Anchors | 1 | 2017 | 5 | 0.560 |
Why?
|
| Pubic Bone | 1 | 2017 | 9 | 0.560 |
Why?
|
| Urination | 3 | 2016 | 40 | 0.550 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 165 | 0.550 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 48 | 0.550 |
Why?
|
| Ureteral Diseases | 1 | 2016 | 14 | 0.530 |
Why?
|
| Surgical Wound | 1 | 2016 | 6 | 0.530 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 129 | 0.530 |
Why?
|
| Free Tissue Flaps | 1 | 2017 | 50 | 0.520 |
Why?
|
| Surgical Flaps | 3 | 2014 | 254 | 0.520 |
Why?
|
| Middle Aged | 36 | 2020 | 26555 | 0.500 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 5 | 0.490 |
Why?
|
| Hysterectomy | 1 | 2016 | 156 | 0.480 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 68 | 0.470 |
Why?
|
| Follow-Up Studies | 19 | 2016 | 3716 | 0.470 |
Why?
|
| Aged | 33 | 2020 | 19574 | 0.460 |
Why?
|
| Urinary Bladder Neck Obstruction | 5 | 2015 | 21 | 0.460 |
Why?
|
| Urinary Tract Infections | 4 | 2017 | 75 | 0.410 |
Why?
|
| Urinary Bladder Diseases | 4 | 2008 | 41 | 0.410 |
Why?
|
| Quality Improvement | 1 | 2016 | 460 | 0.390 |
Why?
|
| Urodynamics | 7 | 2020 | 123 | 0.390 |
Why?
|
| Female | 32 | 2020 | 47186 | 0.380 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2016 | 367 | 0.370 |
Why?
|
| Aged, 80 and over | 16 | 2017 | 6847 | 0.350 |
Why?
|
| Treatment Outcome | 16 | 2016 | 8436 | 0.350 |
Why?
|
| Risk Factors | 8 | 2016 | 5608 | 0.340 |
Why?
|
| Rectus Abdominis | 2 | 2008 | 40 | 0.340 |
Why?
|
| Uterine Prolapse | 2 | 2008 | 82 | 0.330 |
Why?
|
| Surgical Mesh | 2 | 2008 | 125 | 0.330 |
Why?
|
| Cystoscopy | 4 | 2015 | 38 | 0.320 |
Why?
|
| Penile Implantation | 1 | 2009 | 14 | 0.320 |
Why?
|
| Databases, Factual | 4 | 2020 | 882 | 0.310 |
Why?
|
| Transsexualism | 1 | 2009 | 34 | 0.310 |
Why?
|
| Prostatism | 1 | 2008 | 5 | 0.310 |
Why?
|
| Botulinum Toxins | 1 | 2008 | 17 | 0.300 |
Why?
|
| Adult | 22 | 2020 | 27147 | 0.300 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2008 | 15 | 0.300 |
Why?
|
| Vesicovaginal Fistula | 1 | 2008 | 12 | 0.300 |
Why?
|
| Urination Disorders | 1 | 2008 | 52 | 0.300 |
Why?
|
| Sacrum | 2 | 2017 | 44 | 0.280 |
Why?
|
| Prostatic Neoplasms | 6 | 2000 | 1757 | 0.280 |
Why?
|
| United States | 8 | 2017 | 7188 | 0.270 |
Why?
|
| Diagnostic Techniques, Urological | 2 | 2017 | 14 | 0.270 |
Why?
|
| Quality of Life | 5 | 2008 | 1699 | 0.260 |
Why?
|
| Iatrogenic Disease | 2 | 2016 | 71 | 0.260 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 159 | 0.260 |
Why?
|
| Time Factors | 8 | 2016 | 5378 | 0.260 |
Why?
|
| Cysts | 1 | 2007 | 106 | 0.260 |
Why?
|
| Retrospective Studies | 14 | 2020 | 9400 | 0.250 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2015 | 14 | 0.250 |
Why?
|
| Fournier Gangrene | 1 | 2005 | 2 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2016 | 4367 | 0.250 |
Why?
|
| Tissue Expansion | 1 | 2005 | 19 | 0.250 |
Why?
|
| Scrotum | 1 | 2005 | 18 | 0.250 |
Why?
|
| Morbidity | 2 | 2016 | 151 | 0.250 |
Why?
|
| Fibula | 1 | 2005 | 32 | 0.250 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2005 | 18 | 0.240 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 76 | 0.230 |
Why?
|
| Pancreas Transplantation | 1 | 2005 | 104 | 0.230 |
Why?
|
| Device Removal | 2 | 2017 | 170 | 0.210 |
Why?
|
| Administration, Intravesical | 3 | 2008 | 34 | 0.210 |
Why?
|
| Preoperative Care | 3 | 2000 | 402 | 0.210 |
Why?
|
| Amputation, Traumatic | 1 | 2002 | 9 | 0.200 |
Why?
|
| Hypospadias | 1 | 2002 | 7 | 0.200 |
Why?
|
| Prostate-Specific Antigen | 3 | 2000 | 343 | 0.200 |
Why?
|
| Urology | 2 | 2001 | 124 | 0.200 |
Why?
|
| Nephrectomy | 2 | 2015 | 295 | 0.200 |
Why?
|
| Anastomosis, Surgical | 3 | 2016 | 278 | 0.190 |
Why?
|
| Fascia | 1 | 2001 | 31 | 0.190 |
Why?
|
| Incidence | 2 | 2016 | 1599 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2001 | 608 | 0.180 |
Why?
|
| Biofeedback, Psychology | 1 | 2000 | 13 | 0.180 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2000 | 10 | 0.180 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 79 | 0.170 |
Why?
|
| Exercise Therapy | 1 | 2000 | 88 | 0.170 |
Why?
|
| Pressure | 2 | 2019 | 165 | 0.170 |
Why?
|
| Ureteral Obstruction | 2 | 2002 | 69 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 206 | 0.160 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 72 | 0.160 |
Why?
|
| Collagen | 1 | 2000 | 296 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 172 | 0.150 |
Why?
|
| Cryosurgery | 2 | 1995 | 59 | 0.150 |
Why?
|
| Phytotherapy | 1 | 1999 | 136 | 0.150 |
Why?
|
| Urinary Catheterization | 4 | 2014 | 36 | 0.150 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1997 | 6 | 0.140 |
Why?
|
| Platinum Compounds | 1 | 1997 | 28 | 0.140 |
Why?
|
| Seminoma | 1 | 1997 | 14 | 0.140 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 36 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 2017 | 71 | 0.140 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2008 | 40 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 46 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 758 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 12 | 0.130 |
Why?
|
| Creatinine | 1 | 1997 | 295 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2017 | 235 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 115 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2017 | 185 | 0.130 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 222 | 0.130 |
Why?
|
| Pelvis | 1 | 2016 | 96 | 0.130 |
Why?
|
| Orchiectomy | 1 | 1996 | 61 | 0.130 |
Why?
|
| Anilides | 1 | 1996 | 45 | 0.130 |
Why?
|
| Operative Time | 1 | 2016 | 150 | 0.130 |
Why?
|
| Abdomen | 1 | 2016 | 125 | 0.120 |
Why?
|
| Organ Size | 1 | 2016 | 375 | 0.120 |
Why?
|
| Rupture | 1 | 2015 | 61 | 0.120 |
Why?
|
| Rhabdomyolysis | 1 | 2015 | 28 | 0.120 |
Why?
|
| Recurrence | 2 | 2016 | 1170 | 0.120 |
Why?
|
| Survival Rate | 3 | 2015 | 1898 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2016 | 321 | 0.120 |
Why?
|
| Steroids | 1 | 2016 | 173 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 148 | 0.120 |
Why?
|
| Age Factors | 3 | 2016 | 1876 | 0.120 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 139 | 0.120 |
Why?
|
| Linear Models | 1 | 2016 | 426 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 662 | 0.120 |
Why?
|
| Illinois | 1 | 2016 | 499 | 0.120 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2013 | 26 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2013 | 2904 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 300 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 290 | 0.110 |
Why?
|
| Urinary Fistula | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ileum | 1 | 2014 | 168 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 283 | 0.110 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 863 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2015 | 433 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2002 | 31 | 0.100 |
Why?
|
| Sepsis | 1 | 2016 | 330 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 630 | 0.100 |
Why?
|
| Delirium | 1 | 2012 | 73 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 803 | 0.100 |
Why?
|
| Urinary Tract | 2 | 2005 | 34 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2785 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 800 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 475 | 0.090 |
Why?
|
| Kidney | 1 | 1995 | 1153 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1995 | 1374 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2012 | 887 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2000 | 38 | 0.080 |
Why?
|
| Hypertension | 1 | 1994 | 757 | 0.070 |
Why?
|
| Stents | 2 | 2002 | 416 | 0.070 |
Why?
|
| Substance P | 1 | 2008 | 62 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2007 | 4 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 23 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 2022 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2008 | 1226 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2008 | 307 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1073 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2007 | 158 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 234 | 0.070 |
Why?
|
| Valsalva Maneuver | 1 | 2006 | 6 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2003 | 1892 | 0.060 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2005 | 4 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Prostate | 2 | 2003 | 410 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 464 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 1997 | 222 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2347 | 0.060 |
Why?
|
| Duodenum | 1 | 2005 | 105 | 0.060 |
Why?
|
| Internet | 3 | 2001 | 324 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2005 | 233 | 0.060 |
Why?
|
| Lithotripsy | 2 | 2000 | 46 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 152 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2003 | 3 | 0.050 |
Why?
|
| Rats | 3 | 2008 | 4043 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2000 | 360 | 0.050 |
Why?
|
| Urinary Bladder Calculi | 1 | 2002 | 2 | 0.050 |
Why?
|
| Finasteride | 1 | 2002 | 8 | 0.050 |
Why?
|
| International Cooperation | 1 | 2003 | 126 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 420 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 80 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1877 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2000 | 2682 | 0.050 |
Why?
|
| Elasticity | 1 | 2001 | 101 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2001 | 83 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 982 | 0.050 |
Why?
|
| Cadaver | 1 | 2001 | 186 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 615 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2008 | 767 | 0.050 |
Why?
|
| Postal Service | 1 | 2001 | 16 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 204 | 0.050 |
Why?
|
| Professional Practice | 1 | 2001 | 45 | 0.040 |
Why?
|
| Ureteral Calculi | 1 | 2000 | 10 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 351 | 0.040 |
Why?
|
| Cefazolin | 1 | 2000 | 7 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2000 | 85 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 30 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 24 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2001 | 280 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 233 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2001 | 322 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 239 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 91 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 196 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 89 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 1997 | 23 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 3825 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2000 | 343 | 0.030 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 8 | 0.030 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 32 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 245 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 1996 | 13 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1609 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 673 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 2020 | 0.030 |
Why?
|
| Contracture | 1 | 2015 | 19 | 0.030 |
Why?
|
| Nitriles | 1 | 1996 | 157 | 0.030 |
Why?
|
| Chicago | 1 | 1999 | 1452 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 67 | 0.030 |
Why?
|
| Microsurgery | 1 | 2014 | 93 | 0.030 |
Why?
|
| Intestines | 1 | 2016 | 419 | 0.030 |
Why?
|
| Logistic Models | 1 | 1997 | 1216 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 354 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 25 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 219 | 0.030 |
Why?
|
| Groin | 1 | 2012 | 9 | 0.020 |
Why?
|
| Animals | 4 | 2008 | 27783 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 681 | 0.020 |
Why?
|
| Biopsy | 1 | 1994 | 1196 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 854 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1063 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1085 | 0.020 |
Why?
|
| Urothelium | 1 | 2008 | 64 | 0.020 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2005 | 1 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 1713 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 997 | 0.010 |
Why?
|
| Contraindications | 1 | 2000 | 70 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2000 | 46 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 590 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 804 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 238 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 855 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 377 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 960 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 88 | 0.010 |
Why?
|
| Robotics | 1 | 2000 | 269 | 0.010 |
Why?
|
| Child | 2 | 2000 | 7273 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 481 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1997 | 123 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 117 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1738 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 284 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1998 | 1500 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1996 | 500 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 3204 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1169 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2000 | 3790 | 0.010 |
Why?
|
| Hospitalization | 1 | 1997 | 903 | 0.010 |
Why?
|
| Adolescent | 1 | 1997 | 9411 | 0.000 |
Why?
|